Advertisement
UK markets close in 7 hours 7 minutes
  • FTSE 100

    7,853.99
    -111.54 (-1.40%)
     
  • FTSE 250

    19,391.34
    -307.55 (-1.56%)
     
  • AIM

    741.70
    -8.58 (-1.14%)
     
  • GBP/EUR

    1.1718
    +0.0007 (+0.06%)
     
  • GBP/USD

    1.2440
    -0.0006 (-0.05%)
     
  • Bitcoin GBP

    50,920.95
    -2,330.67 (-4.38%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     
  • S&P 500

    5,061.82
    -61.59 (-1.20%)
     
  • DOW

    37,735.11
    -248.13 (-0.65%)
     
  • CRUDE OIL

    85.32
    -0.09 (-0.11%)
     
  • GOLD FUTURES

    2,383.50
    +0.50 (+0.02%)
     
  • NIKKEI 225

    38,471.20
    -761.60 (-1.94%)
     
  • HANG SENG

    16,246.30
    -354.16 (-2.13%)
     
  • DAX

    17,777.89
    -248.69 (-1.38%)
     
  • CAC 40

    7,942.10
    -103.01 (-1.28%)
     

Global Biomarkers Market to Reach $235.2 Billion by 2030

ReportLinker
ReportLinker

The global economy is at a critical crossroads with a number of interlocking challenges and crises running in parallel. The uncertainty around how Russia`s war on Ukraine will play out this year and the war`s role in creating global instability means that the trouble on the inflation front is not over yet.

New York, March 06, 2023 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Global Biomarkers Industry" - https://www.reportlinker.com/p05818140/?utm_source=GNW
Food and fuel inflation will remain a persistent economic problem. Higher retail inflation will impact consumer confidence and spending. As governments combat inflation by raising interest rates, new job creation will slowdown and impact economic activity and growth. Lower capital expenditure is in the offing as companies go slow on investments, held back by inflation worries and weaker demand. With slower growth and high inflation, developed markets seem primed to enter into a recession. Fears of new COVID outbreaks and China’s already uncertain post-pandemic path poses a real risk of the world experiencing more acute supply chain pain and manufacturing disruptions this year. Volatile financial markets, growing trade tensions, stricter regulatory environment and pressure to mainstream climate change into economic decisions will compound the complexity of challenges faced. Year 2023 is expected to be tough year for most markets, investors and consumers. Nevertheless, there is always opportunity for businesses and their leaders who can chart a path forward with resilience and adaptability.

Global Biomarkers Market to Reach $235.2 Billion by 2030

In the changed post COVID-19 business landscape, the global market for Biomarkers estimated at US$69.1 Billion in the year 2022, is projected to reach a revised size of US$235.2 Billion by 2030, growing at aCAGR of 16.5% over the period 2022-2030. Safety, one of the segments analyzed in the report, is projected to record 16.8% CAGR and reach US$89.8 Billion by the end of the analysis period. Taking into account the ongoing post pandemic recovery, growth in the Efficacy segment is readjusted to a revised 14.4% CAGR for the next 8-year period.

The U.S. Market is Estimated at $18.8 Billion, While China is Forecast to Grow at 22.2% CAGR

The Biomarkers market in the U.S. is estimated at US$18.8 Billion in the year 2022. China, the world`s second largest economy, is forecast to reach a projected market size of US$57.8 Billion by the year 2030 trailing a CAGR of 22.2% over the analysis period 2022 to 2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 10.9% and 14.2% respectively over the 2022-2030 period. Within Europe, Germany is forecast to grow at approximately 12.4% CAGR.

Select Competitors (Total 282 Featured)
- Abbott Molecular, Inc.
- Agilent Technologies, Inc.
- Bio-Rad Laboratories, Inc.
- Epigenomics AG
- F. Hoffmann-La Roche AG
- Johnson & Johnson
- QIAGEN NV
- Siemens Healthineers
- Thermo Fisher Scientific, Inc.


Read the full report: https://www.reportlinker.com/p05818140/?utm_source=GNW

I. METHODOLOGY

II. EXECUTIVE SUMMARY

1. MARKET OVERVIEW
Influencer Market Insights
World Market Trajectories
Biomarkers - Global Key Competitors Percentage Market Share in
2022 (E)
Competitive Market Presence - Strong/Active/Niche/Trivial for
Players Worldwide in 2022 (E)
Impact of Covid-19 and a Looming Global Recession

2. FOCUS ON SELECT PLAYERS

3. MARKET TRENDS & DRIVERS

4. GLOBAL MARKET PERSPECTIVE
Table 1: World Recent Past, Current & Future Analysis for
Biomarkers by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific, Latin America, Middle East and Africa
Markets - Independent Analysis of Annual Sales in US$ Million
for Years 2022 through 2030 and % CAGR

Table 2: World Historic Review for Biomarkers by Geographic
Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin
America, Middle East and Africa Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2014 through 2021 and
% CAGR

Table 3: World 16-Year Perspective for Biomarkers by Geographic
Region - Percentage Breakdown of Value Sales for USA, Canada,
Japan, China, Europe, Asia-Pacific, Latin America, Middle East
and Africa Markets for Years 2014, 2023 & 2030

Table 4: World Recent Past, Current & Future Analysis for
Safety by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific, Latin America, Middle East and Africa
Markets - Independent Analysis of Annual Sales in US$ Million
for Years 2022 through 2030 and % CAGR

Table 5: World Historic Review for Safety by Geographic Region -
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin
America, Middle East and Africa Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2014 through 2021 and
% CAGR

Table 6: World 16-Year Perspective for Safety by Geographic
Region - Percentage Breakdown of Value Sales for USA, Canada,
Japan, China, Europe, Asia-Pacific, Latin America, Middle East
and Africa for Years 2014, 2023 & 2030

Table 7: World Recent Past, Current & Future Analysis for
Efficacy by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific, Latin America, Middle East and Africa
Markets - Independent Analysis of Annual Sales in US$ Million
for Years 2022 through 2030 and % CAGR

Table 8: World Historic Review for Efficacy by Geographic
Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin
America, Middle East and Africa Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2014 through 2021 and
% CAGR

Table 9: World 16-Year Perspective for Efficacy by Geographic
Region - Percentage Breakdown of Value Sales for USA, Canada,
Japan, China, Europe, Asia-Pacific, Latin America, Middle East
and Africa for Years 2014, 2023 & 2030

Table 10: World Recent Past, Current & Future Analysis for
Validation by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific, Latin America, Middle East and Africa
Markets - Independent Analysis of Annual Sales in US$ Million
for Years 2022 through 2030 and % CAGR

Table 11: World Historic Review for Validation by Geographic
Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin
America, Middle East and Africa Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2014 through 2021 and
% CAGR

Table 12: World 16-Year Perspective for Validation by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2014, 2023 & 2030

Table 13: World Recent Past, Current & Future Analysis for
Other Applications by Geographic Region - USA, Canada, Japan,
China, Europe, Asia-Pacific, Latin America, Middle East and
Africa Markets - Independent Analysis of Annual Sales in US$
Million for Years 2022 through 2030 and % CAGR

Table 14: World Historic Review for Other Applications by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2014 through 2021 and % CAGR

Table 15: World 16-Year Perspective for Other Applications by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2014, 2023 & 2030

Table 16: World Recent Past, Current & Future Analysis for
Cancer by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific, Latin America, Middle East and Africa
Markets - Independent Analysis of Annual Sales in US$ Million
for Years 2022 through 2030 and % CAGR

Table 17: World Historic Review for Cancer by Geographic Region -
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin
America, Middle East and Africa Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2014 through 2021 and
% CAGR

Table 18: World 16-Year Perspective for Cancer by Geographic
Region - Percentage Breakdown of Value Sales for USA, Canada,
Japan, China, Europe, Asia-Pacific, Latin America, Middle East
and Africa for Years 2014, 2023 & 2030

Table 19: World Recent Past, Current & Future Analysis for
Cardiovascular Diseases by Geographic Region - USA, Canada,
Japan, China, Europe, Asia-Pacific, Latin America, Middle East
and Africa Markets - Independent Analysis of Annual Sales in
US$ Million for Years 2022 through 2030 and % CAGR

Table 20: World Historic Review for Cardiovascular Diseases by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2014 through 2021 and % CAGR

Table 21: World 16-Year Perspective for Cardiovascular Diseases
by Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2014, 2023 & 2030

Table 22: World Recent Past, Current & Future Analysis for
Neurological Diseases by Geographic Region - USA, Canada,
Japan, China, Europe, Asia-Pacific, Latin America, Middle East
and Africa Markets - Independent Analysis of Annual Sales in
US$ Million for Years 2022 through 2030 and % CAGR

Table 23: World Historic Review for Neurological Diseases by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2014 through 2021 and % CAGR

Table 24: World 16-Year Perspective for Neurological Diseases
by Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2014, 2023 & 2030

Table 25: World Recent Past, Current & Future Analysis for
Immunological Diseases by Geographic Region - USA, Canada,
Japan, China, Europe, Asia-Pacific, Latin America, Middle East
and Africa Markets - Independent Analysis of Annual Sales in
US$ Million for Years 2022 through 2030 and % CAGR

Table 26: World Historic Review for Immunological Diseases by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2014 through 2021 and % CAGR

Table 27: World 16-Year Perspective for Immunological Diseases
by Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2014, 2023 & 2030

Table 28: World Recent Past, Current & Future Analysis for
Other Diseases by Geographic Region - USA, Canada, Japan,
China, Europe, Asia-Pacific, Latin America, Middle East and
Africa Markets - Independent Analysis of Annual Sales in US$
Million for Years 2022 through 2030 and % CAGR

Table 29: World Historic Review for Other Diseases by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2014 through 2021 and % CAGR

Table 30: World 16-Year Perspective for Other Diseases by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2014, 2023 & 2030

Table 31: World Recent Past, Current & Future Analysis for Drug
Discovery & Development by Geographic Region - USA, Canada,
Japan, China, Europe, Asia-Pacific, Latin America, Middle East
and Africa Markets - Independent Analysis of Annual Sales in
US$ Million for Years 2022 through 2030 and % CAGR

Table 32: World Historic Review for Drug Discovery &
Development by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific, Latin America, Middle East and Africa
Markets - Independent Analysis of Annual Sales in US$ Million
for Years 2014 through 2021 and % CAGR

Table 33: World 16-Year Perspective for Drug Discovery &
Development by Geographic Region - Percentage Breakdown of
Value Sales for USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa for Years
2014, 2023 & 2030

Table 34: World Recent Past, Current & Future Analysis for
Diagnostics by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific, Latin America, Middle East and Africa
Markets - Independent Analysis of Annual Sales in US$ Million
for Years 2022 through 2030 and % CAGR

Table 35: World Historic Review for Diagnostics by Geographic
Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin
America, Middle East and Africa Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2014 through 2021 and
% CAGR

Table 36: World 16-Year Perspective for Diagnostics by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2014, 2023 & 2030

Table 37: World Recent Past, Current & Future Analysis for
Personalized Medicines by Geographic Region - USA, Canada,
Japan, China, Europe, Asia-Pacific, Latin America, Middle East
and Africa Markets - Independent Analysis of Annual Sales in
US$ Million for Years 2022 through 2030 and % CAGR

Table 38: World Historic Review for Personalized Medicines by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2014 through 2021 and % CAGR

Table 39: World 16-Year Perspective for Personalized Medicines
by Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2014, 2023 & 2030

Table 40: World Biomarkers Market Analysis of Annual Sales in
US$ Million for Years 2014 through 2030

III. MARKET ANALYSIS

UNITED STATES
Biomarkers Market Presence - Strong/Active/Niche/Trivial - Key
Competitors in the United States for 2023 (E)
Table 41: USA Recent Past, Current & Future Analysis for
Biomarkers by Type - Safety, Efficacy and Validation -
Independent Analysis of Annual Sales in US$ Million for the
Years 2022 through 2030 and % CAGR

Table 42: USA Historic Review for Biomarkers by Type - Safety,
Efficacy and Validation Markets - Independent Analysis of
Annual Sales in US$ Million for Years 2014 through 2021 and %
CAGR

Table 43: USA 16-Year Perspective for Biomarkers by Type -
Percentage Breakdown of Value Sales for Safety, Efficacy and
Validation for the Years 2014, 2023 & 2030

Table 44: USA Recent Past, Current & Future Analysis for
Biomarkers by Application - Drug Discovery & Development,
Diagnostics, Personalized Medicines and Other Applications -
Independent Analysis of Annual Sales in US$ Million for the
Years 2022 through 2030 and % CAGR

Table 45: USA Historic Review for Biomarkers by Application -
Drug Discovery & Development, Diagnostics, Personalized
Medicines and Other Applications Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2014 through 2021 and
% CAGR

Table 46: USA 16-Year Perspective for Biomarkers by Application -
Percentage Breakdown of Value Sales for Drug Discovery &
Development, Diagnostics, Personalized Medicines and Other
Applications for the Years 2014, 2023 & 2030

Table 47: USA Recent Past, Current & Future Analysis for
Biomarkers by Disease - Cancer, Cardiovascular Diseases,
Neurological Diseases, Immunological Diseases and Other
Diseases - Independent Analysis of Annual Sales in US$ Million
for the Years 2022 through 2030 and % CAGR

Table 48: USA Historic Review for Biomarkers by Disease -
Cancer, Cardiovascular Diseases, Neurological Diseases,
Immunological Diseases and Other Diseases Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2014 through
2021 and % CAGR

Table 49: USA 16-Year Perspective for Biomarkers by Disease -
Percentage Breakdown of Value Sales for Cancer, Cardiovascular
Diseases, Neurological Diseases, Immunological Diseases and
Other Diseases for the Years 2014, 2023 & 2030

CANADA
Table 50: Canada Recent Past, Current & Future Analysis for
Biomarkers by Type - Safety, Efficacy and Validation -
Independent Analysis of Annual Sales in US$ Million for the
Years 2022 through 2030 and % CAGR

Table 51: Canada Historic Review for Biomarkers by Type -
Safety, Efficacy and Validation Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2014 through 2021 and
% CAGR

Table 52: Canada 16-Year Perspective for Biomarkers by Type -
Percentage Breakdown of Value Sales for Safety, Efficacy and
Validation for the Years 2014, 2023 & 2030

Table 53: Canada Recent Past, Current & Future Analysis for
Biomarkers by Application - Drug Discovery & Development,
Diagnostics, Personalized Medicines and Other Applications -
Independent Analysis of Annual Sales in US$ Million for the
Years 2022 through 2030 and % CAGR

Table 54: Canada Historic Review for Biomarkers by Application -
Drug Discovery & Development, Diagnostics, Personalized
Medicines and Other Applications Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2014 through 2021 and
% CAGR

Table 55: Canada 16-Year Perspective for Biomarkers by
Application - Percentage Breakdown of Value Sales for Drug
Discovery & Development, Diagnostics, Personalized Medicines
and Other Applications for the Years 2014, 2023 & 2030

Table 56: Canada Recent Past, Current & Future Analysis for
Biomarkers by Disease - Cancer, Cardiovascular Diseases,
Neurological Diseases, Immunological Diseases and Other
Diseases - Independent Analysis of Annual Sales in US$ Million
for the Years 2022 through 2030 and % CAGR

Table 57: Canada Historic Review for Biomarkers by Disease -
Cancer, Cardiovascular Diseases, Neurological Diseases,
Immunological Diseases and Other Diseases Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2014 through
2021 and % CAGR

Table 58: Canada 16-Year Perspective for Biomarkers by Disease -
Percentage Breakdown of Value Sales for Cancer,
Cardiovascular Diseases, Neurological Diseases, Immunological
Diseases and Other Diseases for the Years 2014, 2023 & 2030

JAPAN
Biomarkers Market Presence - Strong/Active/Niche/Trivial - Key
Competitors in Japan for 2023 (E)
Table 59: Japan Recent Past, Current & Future Analysis for
Biomarkers by Type - Safety, Efficacy and Validation -
Independent Analysis of Annual Sales in US$ Million for the
Years 2022 through 2030 and % CAGR

Table 60: Japan Historic Review for Biomarkers by Type -
Safety, Efficacy and Validation Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2014 through 2021 and
% CAGR

Table 61: Japan 16-Year Perspective for Biomarkers by Type -
Percentage Breakdown of Value Sales for Safety, Efficacy and
Validation for the Years 2014, 2023 & 2030

Table 62: Japan Recent Past, Current & Future Analysis for
Biomarkers by Application - Drug Discovery & Development,
Diagnostics, Personalized Medicines and Other Applications -
Independent Analysis of Annual Sales in US$ Million for the
Years 2022 through 2030 and % CAGR

Table 63: Japan Historic Review for Biomarkers by Application -
Drug Discovery & Development, Diagnostics, Personalized
Medicines and Other Applications Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2014 through 2021 and
% CAGR

Table 64: Japan 16-Year Perspective for Biomarkers by
Application - Percentage Breakdown of Value Sales for Drug
Discovery & Development, Diagnostics, Personalized Medicines
and Other Applications for the Years 2014, 2023 & 2030

Table 65: Japan Recent Past, Current & Future Analysis for
Biomarkers by Disease - Cancer, Cardiovascular Diseases,
Neurological Diseases, Immunological Diseases and Other
Diseases - Independent Analysis of Annual Sales in US$ Million
for the Years 2022 through 2030 and % CAGR

Table 66: Japan Historic Review for Biomarkers by Disease -
Cancer, Cardiovascular Diseases, Neurological Diseases,
Immunological Diseases and Other Diseases Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2014 through
2021 and % CAGR

Table 67: Japan 16-Year Perspective for Biomarkers by Disease -
Percentage Breakdown of Value Sales for Cancer, Cardiovascular
Diseases, Neurological Diseases, Immunological Diseases and
Other Diseases for the Years 2014, 2023 & 2030

CHINA
Biomarkers Market Presence - Strong/Active/Niche/Trivial - Key
Competitors in China for 2023 (E)
Table 68: China Recent Past, Current & Future Analysis for
Biomarkers by Type - Safety, Efficacy and Validation -
Independent Analysis of Annual Sales in US$ Million for the
Years 2022 through 2030 and % CAGR

Table 69: China Historic Review for Biomarkers by Type -
Safety, Efficacy and Validation Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2014 through 2021 and
% CAGR

Table 70: China 16-Year Perspective for Biomarkers by Type -
Percentage Breakdown of Value Sales for Safety, Efficacy and
Validation for the Years 2014, 2023 & 2030

Table 71: China Recent Past, Current & Future Analysis for
Biomarkers by Application - Drug Discovery & Development,
Diagnostics, Personalized Medicines and Other Applications -
Independent Analysis of Annual Sales in US$ Million for the
Years 2022 through 2030 and % CAGR

Table 72: China Historic Review for Biomarkers by Application -
Drug Discovery & Development, Diagnostics, Personalized
Medicines and Other Applications Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2014 through 2021 and
% CAGR

Table 73: China 16-Year Perspective for Biomarkers by
Application - Percentage Breakdown of Value Sales for Drug
Discovery & Development, Diagnostics, Personalized Medicines
and Other Applications for the Years 2014, 2023 & 2030

Table 74: China Recent Past, Current & Future Analysis for
Biomarkers by Disease - Cancer, Cardiovascular Diseases,
Neurological Diseases, Immunological Diseases and Other
Diseases - Independent Analysis of Annual Sales in US$ Million
for the Years 2022 through 2030 and % CAGR

Table 75: China Historic Review for Biomarkers by Disease -
Cancer, Cardiovascular Diseases, Neurological Diseases,
Immunological Diseases and Other Diseases Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2014 through
2021 and % CAGR

Table 76: China 16-Year Perspective for Biomarkers by Disease -
Percentage Breakdown of Value Sales for Cancer, Cardiovascular
Diseases, Neurological Diseases, Immunological Diseases and
Other Diseases for the Years 2014, 2023 & 2030

EUROPE
Biomarkers Market Presence - Strong/Active/Niche/Trivial - Key
Competitors in Europe for 2023 (E)
Table 77: Europe Recent Past, Current & Future Analysis for
Biomarkers by Geographic Region - France, Germany, Italy, UK,
Spain, Russia and Rest of Europe Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2022 through 2030 and
% CAGR

Table 78: Europe Historic Review for Biomarkers by Geographic
Region - France, Germany, Italy, UK, Spain, Russia and Rest of
Europe Markets - Independent Analysis of Annual Sales in US$
Million for Years 2014 through 2021 and % CAGR

Table 79: Europe 16-Year Perspective for Biomarkers by
Geographic Region - Percentage Breakdown of Value Sales for
France, Germany, Italy, UK, Spain, Russia and Rest of Europe
Markets for Years 2014, 2023 & 2030

Table 80: Europe Recent Past, Current & Future Analysis for
Biomarkers by Type - Safety, Efficacy and Validation -
Independent Analysis of Annual Sales in US$ Million for the
Years 2022 through 2030 and % CAGR

Table 81: Europe Historic Review for Biomarkers by Type -
Safety, Efficacy and Validation Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2014 through 2021 and
% CAGR

Table 82: Europe 16-Year Perspective for Biomarkers by Type -
Percentage Breakdown of Value Sales for Safety, Efficacy and
Validation for the Years 2014, 2023 & 2030

Table 83: Europe Recent Past, Current & Future Analysis for
Biomarkers by Application - Drug Discovery & Development,
Diagnostics, Personalized Medicines and Other Applications -
Independent Analysis of Annual Sales in US$ Million for the
Years 2022 through 2030 and % CAGR

Table 84: Europe Historic Review for Biomarkers by Application -
Drug Discovery & Development, Diagnostics, Personalized
Medicines and Other Applications Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2014 through 2021 and
% CAGR

Table 85: Europe 16-Year Perspective for Biomarkers by
Application - Percentage Breakdown of Value Sales for Drug
Discovery & Development, Diagnostics, Personalized Medicines
and Other Applications for the Years 2014, 2023 & 2030

Table 86: Europe Recent Past, Current & Future Analysis for
Biomarkers by Disease - Cancer, Cardiovascular Diseases,
Neurological Diseases, Immunological Diseases and Other
Diseases - Independent Analysis of Annual Sales in US$ Million
for the Years 2022 through 2030 and % CAGR

Table 87: Europe Historic Review for Biomarkers by Disease -
Cancer, Cardiovascular Diseases, Neurological Diseases,
Immunological Diseases and Other Diseases Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2014 through
2021 and % CAGR

Table 88: Europe 16-Year Perspective for Biomarkers by Disease -
Percentage Breakdown of Value Sales for Cancer,
Cardiovascular Diseases, Neurological Diseases, Immunological
Diseases and Other Diseases for the Years 2014, 2023 & 2030

FRANCE
Biomarkers Market Presence - Strong/Active/Niche/Trivial - Key
Competitors in France for 2023 (E)
Table 89: France Recent Past, Current & Future Analysis for
Biomarkers by Type - Safety, Efficacy and Validation -
Independent Analysis of Annual Sales in US$ Million for the
Years 2022 through 2030 and % CAGR

Table 90: France Historic Review for Biomarkers by Type -
Safety, Efficacy and Validation Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2014 through 2021 and
% CAGR

Table 91: France 16-Year Perspective for Biomarkers by Type -
Percentage Breakdown of Value Sales for Safety, Efficacy and
Validation for the Years 2014, 2023 & 2030

Table 92: France Recent Past, Current & Future Analysis for
Biomarkers by Application - Drug Discovery & Development,
Diagnostics, Personalized Medicines and Other Applications -
Independent Analysis of Annual Sales in US$ Million for the
Years 2022 through 2030 and % CAGR

Table 93: France Historic Review for Biomarkers by Application -
Drug Discovery & Development, Diagnostics, Personalized
Medicines and Other Applications Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2014 through 2021 and
% CAGR

Table 94: France 16-Year Perspective for Biomarkers by
Application - Percentage Breakdown of Value Sales for Drug
Discovery & Development, Diagnostics, Personalized Medicines
and Other Applications for the Years 2014, 2023 & 2030

Table 95: France Recent Past, Current & Future Analysis for
Biomarkers by Disease - Cancer, Cardiovascular Diseases,
Neurological Diseases, Immunological Diseases and Other
Diseases - Independent Analysis of Annual Sales in US$ Million
for the Years 2022 through 2030 and % CAGR

Table 96: France Historic Review for Biomarkers by Disease -
Cancer, Cardiovascular Diseases, Neurological Diseases,
Immunological Diseases and Other Diseases Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2014 through
2021 and % CAGR

Table 97: France 16-Year Perspective for Biomarkers by Disease -
Percentage Breakdown of Value Sales for Cancer,
Cardiovascular Diseases, Neurological Diseases, Immunological
Diseases and Other Diseases for the Years 2014, 2023 & 2030

GERMANY
Biomarkers Market Presence - Strong/Active/Niche/Trivial - Key
Competitors in Germany for 2023 (E)
Table 98: Germany Recent Past, Current & Future Analysis for
Biomarkers by Type - Safety, Efficacy and Validation -
Independent Analysis of Annual Sales in US$ Million for the
Years 2022 through 2030 and % CAGR

Table 99: Germany Historic Review for Biomarkers by Type -
Safety, Efficacy and Validation Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2014 through 2021 and
% CAGR

Table 100: Germany 16-Year Perspective for Biomarkers by Type -
Percentage Breakdown of Value Sales for Safety, Efficacy and
Validation for the Years 2014, 2023 & 2030

Table 101: Germany Recent Past, Current & Future Analysis for
Biomarkers by Application - Drug Discovery & Development,
Diagnostics, Personalized Medicines and Other Applications -
Independent Analysis of Annual Sales in US$ Million for the
Years 2022 through 2030 and % CAGR

Table 102: Germany Historic Review for Biomarkers by
Application - Drug Discovery & Development, Diagnostics,
Personalized Medicines and Other Applications Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2014 through 2021 and % CAGR

Table 103: Germany 16-Year Perspective for Biomarkers by
Application - Percentage Breakdown of Value Sales for Drug
Discovery & Development, Diagnostics, Personalized Medicines
and Other Applications for the Years 2014, 2023 & 2030

Table 104: Germany Recent Past, Current & Future Analysis for
Biomarkers by Disease - Cancer, Cardiovascular Diseases,
Neurological Diseases, Immunological Diseases and Other
Diseases - Independent Analysis of Annual Sales in US$ Million
for the Years 2022 through 2030 and % CAGR

Table 105: Germany Historic Review for Biomarkers by Disease -
Cancer, Cardiovascular Diseases, Neurological Diseases,
Immunological Diseases and Other Diseases Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2014 through
2021 and % CAGR

Table 106: Germany 16-Year Perspective for Biomarkers by
Disease - Percentage Breakdown of Value Sales for Cancer,
Cardiovascular Diseases, Neurological Diseases, Immunological
Diseases and Other Diseases for the Years 2014, 2023 & 2030

ITALY
Table 107: Italy Recent Past, Current & Future Analysis for
Biomarkers by Type - Safety, Efficacy and Validation -
Independent Analysis of Annual Sales in US$ Million for the
Years 2022 through 2030 and % CAGR

Table 108: Italy Historic Review for Biomarkers by Type -
Safety, Efficacy and Validation Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2014 through 2021 and
% CAGR

Table 109: Italy 16-Year Perspective for Biomarkers by Type -
Percentage Breakdown of Value Sales for Safety, Efficacy and
Validation for the Years 2014, 2023 & 2030

Table 110: Italy Recent Past, Current & Future Analysis for
Biomarkers by Application - Drug Discovery & Development,
Diagnostics, Personalized Medicines and Other Applications -
Independent Analysis of Annual Sales in US$ Million for the
Years 2022 through 2030 and % CAGR

Table 111: Italy Historic Review for Biomarkers by Application -
Drug Discovery & Development, Diagnostics, Personalized
Medicines and Other Applications Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2014 through 2021 and
% CAGR

Table 112: Italy 16-Year Perspective for Biomarkers by
Application - Percentage Breakdown of Value Sales for Drug
Discovery & Development, Diagnostics, Personalized Medicines
and Other Applications for the Years 2014, 2023 & 2030

Table 113: Italy Recent Past, Current & Future Analysis for
Biomarkers by Disease - Cancer, Cardiovascular Diseases,
Neurological Diseases, Immunological Diseases and Other
Diseases - Independent Analysis of Annual Sales in US$ Million
for the Years 2022 through 2030 and % CAGR

Table 114: Italy Historic Review for Biomarkers by Disease -
Cancer, Cardiovascular Diseases, Neurological Diseases,
Immunological Diseases and Other Diseases Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2014 through
2021 and % CAGR

Table 115: Italy 16-Year Perspective for Biomarkers by Disease -
Percentage Breakdown of Value Sales for Cancer,
Cardiovascular Diseases, Neurological Diseases, Immunological
Diseases and Other Diseases for the Years 2014, 2023 & 2030

UNITED KINGDOM
Biomarkers Market Presence - Strong/Active/Niche/Trivial - Key
Competitors in the United Kingdom for 2023 (E)
Table 116: UK Recent Past, Current & Future Analysis for
Biomarkers by Type - Safety, Efficacy and Validation -
Independent Analysis of Annual Sales in US$ Million for the
Years 2022 through 2030 and % CAGR

Table 117: UK Historic Review for Biomarkers by Type - Safety,
Efficacy and Validation Markets - Independent Analysis of
Annual Sales in US$ Million for Years 2014 through 2021 and %
CAGR

Table 118: UK 16-Year Perspective for Biomarkers by Type -
Percentage Breakdown of Value Sales for Safety, Efficacy and
Validation for the Years 2014, 2023 & 2030

Table 119: UK Recent Past, Current & Future Analysis for
Biomarkers by Application - Drug Discovery & Development,
Diagnostics, Personalized Medicines and Other Applications -
Independent Analysis of Annual Sales in US$ Million for the
Years 2022 through 2030 and % CAGR

Table 120: UK Historic Review for Biomarkers by Application -
Drug Discovery & Development, Diagnostics, Personalized
Medicines and Other Applications Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2014 through 2021 and
% CAGR

Table 121: UK 16-Year Perspective for Biomarkers by Application -
Percentage Breakdown of Value Sales for Drug Discovery &
Development, Diagnostics, Personalized Medicines and Other
Applications for the Years 2014, 2023 & 2030

Table 122: UK Recent Past, Current & Future Analysis for
Biomarkers by Disease - Cancer, Cardiovascular Diseases,
Neurological Diseases, Immunological Diseases and Other
Diseases - Independent Analysis of Annual Sales in US$ Million
for the Years 2022 through 2030 and % CAGR

Table 123: UK Historic Review for Biomarkers by Disease -
Cancer, Cardiovascular Diseases, Neurological Diseases,
Immunological Diseases and Other Diseases Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2014 through
2021 and % CAGR

Table 124: UK 16-Year Perspective for Biomarkers by Disease -
Percentage Breakdown of Value Sales for Cancer, Cardiovascular
Diseases, Neurological Diseases, Immunological Diseases and
Other Diseases for the Years 2014, 2023 & 2030

SPAIN
Table 125: Spain Recent Past, Current & Future Analysis for
Biomarkers by Type - Safety, Efficacy and Validation -
Independent Analysis of Annual Sales in US$ Million for the
Years 2022 through 2030 and % CAGR

Table 126: Spain Historic Review for Biomarkers by Type -
Safety, Efficacy and Validation Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2014 through 2021 and
% CAGR

Please contact our Customer Support Center to get the complete Table of Contents
Read the full report: https://www.reportlinker.com/p05818140/?utm_source=GNW

About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________

CONTACT: Clare: clare@reportlinker.com US: (339)-368-6001 Intl: +1 339-368-6001